Ondansetron chemical structure
Find information on thousands of medical conditions and prescription drugs.

Zofran

Ondansetron is a serotonin 5-HT3 receptor antagonist used mainly to treat nausea and vomiting following chemotherapy. Its effects are thought to be on both peripheral and central nerves. One part is to reduce the activity of the vagus nerve, which is a nerve that activates the vomiting center in the medulla oblongata, the other is a blockage of serotonin receptors in the chemoreceptor trigger zone. It does not have much effect on vomiting due to motion sickness. This drug does not have any effect on dopamine receptors or muscarinic receptors. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Zafirlukast
Zagam
Zalcitabine
Zaleplon
Zanaflex
Zanamivir
Zantac
Zarontin
Zelnorm
Zerit
Zestoretic
Zestril
Zetia
Zevalin
Ziagen
Zidovudine
Zileuton
Ziprasidone
Zithromax
Zocor
Zofran
Zoladex
Zoledronic acid
Zolmitriptan
Zoloft
Zolpidem
Zometa
Zomig
Zonegran
Zonisamide
Zopiclone
Zosyn
Zovia
Zovirax
Zyban
Zymar
Zyprexa
Zyrtec
Zyvox

Ondansetron is broken down in the liver. It's elimination half-life is about 2-3 hours following i.v. administration in patients with normal liver and kidney functions. The drug is usually administered once, twice or three times daily, depending on the severity of nausea and/or vomiting. Following oral administration, it takes about 1.5-2 hours to reach maximum plasma concentrations. This drug is removed from the body by the liver and kidneys.

It is currently marketed by GlaxoSmithKline under the trade name Zofran; other manufacturers include Cipla Ltd (Emeset), Chemical Works of Gedeon Richter (Emetron), and Zentiva a.s. (Ondemet).

Clinical uses

  • Chemotherapy-induced nausea and vomiting
    • 5-HT3 receptor antagonists are the primary drugs used to treat and prevent chemotherapy-induced nausea and vomiting. Many times they are given intravenously about 30 minutes before beginning therapy.
  • Post-operative and post-radiation nausea and vomiting
  • Is a possible therapy for nausea and vomiting due to acute or chronic medical illness or acute gastroenteritis

Although highly effective, its high cost limits its use to controlling postoperative nausea and vomiting (PONV) and chemotherapy-induced nausea and vomiting (CINV). It is also used off-label to treat hyperemesis gravidarum in pregnant women, but there is no conclusive data available on its safety in pregnancy, especially during the first trimester.

Clinical effect of ondansetron (and other drugs from the same group) can be potentiated by combining it with dexamethasone.

Adverse effects

Ondansetron is a well-tolerated drug with few side effects. Headache, constipation, and dizziness are the most commonly reported side effects associated with its use. There have been no significant drug interactions reported with this drug's use. It is broken down by the liver's cytochrome P450 system and it has little effect on the metabolism of other drugs broken down by this system.

Read more at Wikipedia.org


[List your site here Free!]


Antinausea drug appears safe in pregnancy
From OB/GYN News, 12/1/04 by Sharon Worcester

Ondansetron is increasingly prescribed off label for nausea and vomiting in pregnancy, and a new study suggests it is safe for this indication.

In the prospective observational study, the drug, which is typically used for treating nausea and vomiting in cancer chemotherapy patients, was not associated with an increased risk of fetal malformations, reported Adrienne Einarson, R.N., of the University of Toronto and her colleagues (BJOG 2004;111:940-3).

The investigators studied women exposed to ondansetron (Zofran), other antiemetics (including Diclectin, metoclopramide, phenothiazines, and ginger), and/or no drugs or only nonteratogenic drugs. Outcomes from 176 pregnancies in each group have been evaluated.

In the ondansetron group there were 169 live births, five miscarriages, and two therapeutic abortions. There were six major malformations, for a rate of 3.5%. The mean birthweight was 3,362 g. There were no statistical differences between the three groups in any of the study end points.

Ondansetron appears safe for the fetus, but many more cases would need to be studied before a definitive conclusion about the safety of the drug could be made, the investigators said.

COPYRIGHT 2004 International Medical News Group
COPYRIGHT 2004 Gale Group

Return to Zofran
Home Contact Resources Exchange Links ebay